<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028975</url>
  </required_header>
  <id_info>
    <org_study_id>VERGES 2009</org_study_id>
    <nct_id>NCT02028975</nct_id>
  </id_info>
  <brief_title>Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.</brief_title>
  <official_title>Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is
      accompanied by the rapid secretion of hormones in the digestive tract (incretines). We aim to
      determine in healthy humans whether the orosensory perception of fatty acids is followed by a
      modification in plasma levels of digestive tract hormones (cholecystokinin, GIP, GLP-1,
      secretin, pancreatic peptide, peptide YY, insulin) and metabolic markers from adipose tissue
      (leptin, ghrelin, adiponectin).

      We also aim to determine whether the hormonal response induced by orosensory stimulation by
      lipids is modified:

        -  in patients with type 2 diabetes

        -  in obese non-diabetic patients We expect to show an increase in biological markers
           biological, and more particularly in certain digestive hormones such as Pancreatic
           polypeptide, GIP, GLP-1â€¦after stimulation of the lingual lipid receptor, CD36. We will
           also determine whether or not this response is modified in patients with type 2 diabetes
           and in obese non-diabetic patients.

      We also wish to measure the subjects' gustatory detection threshold for a fatty acid
      (linoleic acid), and to determine whether there is a relationship between the orosensory
      perception threshold for linoleic acid and the physiological status of the subjects. In order
      to achieve this, the thresholds for healthy subjects will be compared with thresholds for
      obese and diabetic subjects. Expected results: the threshold of detection for linoleic acid
      in healthy subjects will be lower than that in obese or diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma levels of biological markers of orosensorielle perception fatty acids</measure>
    <time_frame>Change from baseline at 15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure the detection threshold for linoleic acid</measure>
    <time_frame>baselines</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 2 Diabetes or Obesity Without Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Measure the threshold of detection for linoleic acid</intervention_name>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral stimulation tests</intervention_name>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Venous blood samples</intervention_name>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples for genetic studies (ancillary study)</intervention_name>
    <arm_group_label>Patients with type 2 diabetes</arm_group_label>
    <arm_group_label>Obese patients without diabetes</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persons who have provided written consent

          -  Healthy volunteers:

          -  Men &gt; 18 years

          -  19 &lt;BMI &lt; 25 kg.m-2

          -  Fasting triglyceridemia &lt; 1.50 g/l

          -  Fasting glycemia &lt; 1.10 g/l

          -  Without regular medical treatment

          -  Patients with type-2 diabetes:

          -  Men &gt;18 years

          -  type 2 diabetes (fasting glycemia &gt; 7 mmol/l at the diagnosis) treated with diet or
             diet + oral antidiabetics (metformin, and/or insulinsecretion agents [hypoglycemic
             sulphonamides, or glinides] and/or glitazones and/or acarbose)

          -  Stable oral antidiabetic treatment for 3 months

          -  Obese non-diabetic patients:

          -  Men &gt; 18 years

          -  BMI 30 kg.m-2

          -  Fasting glycemia &lt; 1.10 g/l

          -  HbA1c &lt; 6.0%

          -  Absence of treatment with hypoglycemic agents (including benfluorex)

          -  Absence of medical treatment for obesity

          -  Absence of a history of surgery for obesity (band, by-pass) or gastric stimulator
             (type Tantalus)

        Exclusion Criteria:

          -  Persons not covered by the national health insurance

          -  Smokers, or smoking cessation within the 3 months preceding inclusion

          -  Persons with eating disorders:

          -  Severe digestive disease (enteropathy with absorption disorders, inflammatory
             digestive disease)

          -  Pancreatic insufficiency

          -  History of pancreas surgery

          -  Type 1 diabetes

          -  Renal insufficiency

          -  Hepatic insufficiency

          -  Treatment with proton pump inhibitors, insulin, GLP-1 analogues, DPP-4 inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bruno VERGES</last_name>
    <phone>3 80 29 34 53</phone>
    <phone_ext>+33</phone_ext>
    <email>bruno.verges@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle ROBIN</last_name>
      <phone>3 80 29 33 32</phone>
      <phone_ext>+33</phone_ext>
      <email>isabelle.simoneau-robin@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>January 6, 2014</last_update_submitted>
  <last_update_submitted_qc>January 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

